Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

Verdict

Headline takes no side. We score OGN +1.00 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · OGN

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 98% of ticker scores this week

Actual

Scored by the NIS engine · methodology.

• m and a▲27%
• healthcare▲17%
• OGN
• acquisition
• biosimilars
• generics
• india
• pharma